XORTX Therapeutics Inc
XRTX
Company Profile
Business description
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Contact
3710 - 33rd Street NW
CalgaryABT2L 2M1
CANT: +1 403 455-7727
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.60 | 16.00 | -0.18% |
| CAC 40 | 8,382.38 | 15.53 | 0.19% |
| DAX 40 | 25,010.36 | 136.67 | -0.54% |
| Dow JONES (US) | 52,706.73 | 198.46 | 0.38% |
| FTSE 100 | 10,520.92 | 8.47 | -0.08% |
| HKSE | 24,681.10 | 340.37 | 1.40% |
| NASDAQ | 26,190.52 | 83.52 | 0.32% |
| Nikkei 225 | 68,751.51 | 1,008.01 | 1.49% |
| NZX 50 Index | 13,635.07 | 16.15 | -0.12% |
| S&P 500 | 7,562.69 | 19.10 | 0.25% |
| S&P/ASX 200 | 8,841.10 | 15.90 | -0.18% |
| SSE Composite Index | 3,955.58 | 11.55 | -0.29% |